Hepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Almost all patients with chronic liver diseases (CLD) show altered bone metabolism. Depending on the etiology, this manifests in a severe osteoporosis in up to 75% of the affected patients. Due to high prevalence, the generic term hepatic osteodystrophy (HOD) evolved, describing altered bone metabolism, decreased bone mineral density, and deterioration of bone structure in patients with CLD. Once developed, HOD is difficult to treat and increases the risk of fragility fractures. Existing fractures affect the quality of life and, more importantly, long-term prognosis of these patients, which presents with increased mortality. Thus, special care is required to support the healing process. However, for early diagnosis (reduce fracture risk) and development of adequate treatment strategies (support healing of existing fractures), it is essential to understand the underlying mechanisms that link disturbed liver function with this bone phenotype. In the present review, we summarize proposed molecular mechanisms favoring the development of HOD and compromising the healing of associated fractures, including alterations in vitamin D metabolism and action, disbalances in transforming growth factor beta (TGF-β) and bone morphogenetic protein (BMP) signaling with histone deacetylases (HDACs) as secondary regulators, as well as alterations in the receptor activator of nuclear factor kappa B ligand (RANKL)–osteoprotegerin (OPG) system mediated by sclerostin. Based on these mechanisms, we give an overview on the limitations of early diagnosis of HOD with established serum markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitamin D metabolism, mechanism of action, and clinical applications
Bikle, D. D. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.016 · Cited by 1,933
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Self-citationIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698
Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Self-citationMice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559
Cited by
Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression
Lu, K., Shi, T.-S., Shen, S.-Y., Shi, Y., Gao, H.-L., Wu, J., Lu, X., Gao, X., Ju, H.-X., Wang, W., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.006 · Cited by 126
“Our studies add to the knowledge of a crucial liver-bone axis in maintaining themetabolic homeostasis of the body (Ehnert et al., 2019; Nussler et al., 2014; Wang et al., 2015).”
BackgroundSIRT2 regulates extracellular vesicle-mediated liver-bone communication
Lin, L., Guo, Z., He, E., Long, X., Wang, D., Zhang, Y., Guo, W., Wei, Q., He, W., Wu, W., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00803-0 · Cited by 88
Jadzic, J., Milovanovic, P. D., Cvetkovic, D., Zivkovic, V., Nikolic, S., Tomanovic, N., Djuric, M. P., & Djonic, D. (2022) · Journal of Anatomy · doi:10.1111/joa.13621 · Cited by 14
“…activator for nuclear factor kappa B ligand and osteoprotegerin ratio, altered production of pro- inflammatory cytokines and trophic factors (Ehnert et al., 2019; Guañabens & Parés, 2018; Luo et al., 2017), changes in matrix metalloproteinase activity, or bilirubin and bile acids stasis are…”
BackgroundHosseini-Fard, S. R., Etemad-Moghadam, S., Alaeddini, M., Dehpour, A. R., Emamgholipour, S., & Golestani, A. (2024) · Scientific Reports · doi:10.1038/s41598-023-50547-w · Cited by 6
“Researchers are investigating diverse mechanisms that could potentially serve as targets for these treatments 3 .”
Background
Metadata
- Authors
- Ehnert, S., Aspera-Werz, R. H., Ruoß, M., Dooley, S., Hengstler, J. G., Nadalin, S., Relja, B., Badke, A., & Nussler, A. K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-05-24
- Volume
- 20
- Issue
- 10
- Pages
- 2555
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2946475073
- Cited by
- 72
- References
- 41
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.